The Australian medical sector is excited with the introduction of retatrutide, a innovative dual GIP and GLP-1 receptor agonist showing significant results in early trials for managing obesity. This https://get-social-now.com/story7239334/retatrutide-australia-australia-a-potential-hope-for-obesity-treatment